Abrdn PLC Mereo Biopharma Group PLC Call Options Transaction History
Abrdn PLC
- $61.6 Billion
- Q3 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding MREO
# of Institutions
98Shares Held
102MCall Options Held
2.42MPut Options Held
454K-
Janus Henderson Group PLC London, X016.3MShares$29.6 Million0.02% of portfolio
-
Rubric Capital Management LP New York, NY15.3MShares$27.9 Million0.5% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA9.44MShares$17.2 Million0.79% of portfolio
-
Mangrove Partners New York, NY7.79MShares$14.2 Million1.99% of portfolio
-
683 Capital Management, LLC New York, NY4.88MShares$8.87 Million0.57% of portfolio
About Mereo Biopharma Group plc
- Ticker MREO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,986,000
- Market Cap $227M
- Description
- Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...